Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.543CHF
−95.75 MCHF
106.36 MCHF
119.86 M
About Seres Therapeutics, Inc.
Sector
Industry
CEO
Eric D. Shaff
Website
Headquarters
Cambridge
Employees (FY)
233
Founded
2010
FIGI
BBG00LVGDJZ9
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 1S9 is 0.767 CHF — it has decreased by 19.85% in the past 24 hours. Watch SERES THERAPEUTICS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange SERES THERAPEUTICS stocks are traded under the ticker 1S9.
We've gathered analysts' opinions on SERES THERAPEUTICS future price: according to them, 1S9 price has a max estimate of 8.95 CHF and a min estimate of 0.89 CHF. Watch 1S9 chart and read a more detailed SERES THERAPEUTICS stock forecast: see what analysts think of SERES THERAPEUTICS and suggest that you do with its stocks.
1S9 stock is 24.77% volatile and has beta coefficient of 1.66. Track SERES THERAPEUTICS stock price on the chart and check out the list of the most volatile stocks — is SERES THERAPEUTICS there?
Today SERES THERAPEUTICS has the market capitalization of 101.79 M, it has decreased by 43.17% over the last week.
Yes, you can track SERES THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
SERES THERAPEUTICS is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
1S9 earnings for the last quarter are −0.24 CHF per share, whereas the estimation was −0.31 CHF resulting in a 20.98% surprise. The estimated earnings for the next quarter are −0.24 CHF per share. See more details about SERES THERAPEUTICS earnings.
SERES THERAPEUTICS revenue for the last quarter amounts to 0 CHF, despite the estimated figure of 225.53 K CHF. In the next quarter, revenue is expected to reach −236.27 K CHF.
1S9 net income for the last quarter is −36.20 M CHF, while the quarter before that showed −34.73 M CHF of net income which accounts for −4.25% change. Track more SERES THERAPEUTICS financial stats to get the full picture.
No, 1S9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 26, 2024, the company has 233.00 employees. See our rating of the largest employees — is SERES THERAPEUTICS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SERES THERAPEUTICS EBITDA is −57.99 M CHF, and current EBITDA margin is −72.96%. See more stats in SERES THERAPEUTICS financial statements.
Like other stocks, 1S9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SERES THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SERES THERAPEUTICS technincal analysis shows the neutral today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SERES THERAPEUTICS stock shows the sell signal. See more of SERES THERAPEUTICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.